NO964548D0 - Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesity - Google Patents
Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesityInfo
- Publication number
- NO964548D0 NO964548D0 NO964548A NO964548A NO964548D0 NO 964548 D0 NO964548 D0 NO 964548D0 NO 964548 A NO964548 A NO 964548A NO 964548 A NO964548 A NO 964548A NO 964548 D0 NO964548 D0 NO 964548D0
- Authority
- NO
- Norway
- Prior art keywords
- obesity
- agonists
- diabetes
- selective
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23316694A | 1994-04-26 | 1994-04-26 | |
US40456595A | 1995-03-21 | 1995-03-21 | |
US08/404,566 US5541197A (en) | 1994-04-26 | 1995-03-21 | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
PCT/US1995/004956 WO1995029159A1 (en) | 1994-04-26 | 1995-04-21 | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Publications (2)
Publication Number | Publication Date |
---|---|
NO964548D0 true NO964548D0 (en) | 1996-10-25 |
NO964548L NO964548L (en) | 1996-12-23 |
Family
ID=27398391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO964548A NO964548L (en) | 1994-04-26 | 1996-10-25 | Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesity |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0757674A1 (en) |
JP (1) | JP3149186B2 (en) |
CN (1) | CN1149869A (en) |
AU (1) | AU687558B2 (en) |
CA (1) | CA2187932A1 (en) |
CZ (1) | CZ315196A3 (en) |
FI (1) | FI964314A (en) |
HU (1) | HUT76442A (en) |
IL (1) | IL113410A (en) |
NO (1) | NO964548L (en) |
NZ (1) | NZ284718A (en) |
PL (1) | PL316969A1 (en) |
SK (1) | SK136196A3 (en) |
WO (1) | WO1995029159A1 (en) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705515A (en) * | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
GB2305665A (en) * | 1995-09-26 | 1997-04-16 | Merck & Co Inc | Selective ß3 agonists for the treatment of diabetes aand obesity |
JPH11515027A (en) * | 1995-11-01 | 1999-12-21 | メルク エンド カンパニー インコーポレーテッド | Combination therapy for the treatment of diabetes and obesity |
US6037362A (en) * | 1996-01-10 | 2000-03-14 | Asahi Kasei Kogyo Kabushiki Kaisha | Tricyclic compounds and drug compositions containing the same |
AU712057B2 (en) * | 1996-06-07 | 1999-10-28 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity |
AR007739A1 (en) * | 1996-07-22 | 1999-11-10 | Merck & Co Inc | A PROCESS FOR THE PREPARATION OF N- (R) - (2-HYDROXY-2-PIRIDINE-3-IL-ETIL) -2- (4-NITRO-PHENYL) -ACETAMIDE |
US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
YU22099A (en) | 1996-11-14 | 2001-09-28 | Pfizer Inc. | Process for substituted pyridines |
PT842924E (en) * | 1996-11-14 | 2003-12-31 | Pfizer | PYRIDINE INTERMEDIARIES IN THE SYNTHESIS OF BETA-ADRENERGIC RECEPTOR AGONISTS |
EE9900328A (en) * | 1997-01-28 | 2000-02-15 | Merck & Co., Inc. | Thiazole Benzenesulfonamides as β3-Agonists in the Treatment of Diabetes and Obesity |
US6011048A (en) * | 1997-01-28 | 2000-01-04 | Merck & Co., Inc. | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity |
ATE266639T1 (en) * | 1997-10-17 | 2004-05-15 | Yamanouchi Pharma Co Ltd | AMIDE DERIVATIVES OR SALTS THEREOF |
US6469031B1 (en) | 1998-12-18 | 2002-10-22 | Bayer Corporation | Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
US6051586A (en) * | 1997-12-19 | 2000-04-18 | Bayer Corporation | Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
AU751015B2 (en) * | 1997-12-19 | 2002-08-08 | Bayer Corporation | Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
US6043253A (en) * | 1998-03-03 | 2000-03-28 | Merck & Co., Inc. | Fused piperidine substituted arylsulfonamides as β3-agonists |
AU2001272917A1 (en) * | 2000-07-13 | 2002-01-30 | Eli Lilly And Company | Beta3 adrenergic agonists |
US6451814B1 (en) * | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
ES2265447T3 (en) | 2000-11-10 | 2007-02-16 | Eli Lilly And Company | OXINDOL-3-REPLACED BETA-3 RECEIVER AGONISTS. |
AR035605A1 (en) | 2000-12-11 | 2004-06-16 | Bayer Corp | DERIVATIVES OF AMINOMETIL CHROMANO DI-SUBSTITUTES, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3-ADRENE-RECEPTORS AGONISTS |
EP1236723A1 (en) | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
AR035858A1 (en) | 2001-04-23 | 2004-07-21 | Bayer Corp | CHROME DERIVATIVES 2,6-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3 ADRENORRECEPTING AGONISTS |
WO2003016307A1 (en) | 2001-08-14 | 2003-02-27 | Eli Lilly And Company | β3 ADRENERGIC AGONISTS |
ATE325119T1 (en) | 2001-08-14 | 2006-06-15 | Lilly Co Eli | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS |
EP1935882B1 (en) | 2001-10-25 | 2011-02-09 | Asahi Kasei Pharma Corporation | Bicyclic compounds |
ATE297925T1 (en) | 2001-11-20 | 2005-07-15 | Lilly Co Eli | 3-SUBSTITUTED OXINDOL BETA 3 AGONISTS |
US7071208B2 (en) | 2001-11-20 | 2006-07-04 | Eli Lilly And Company | β3 Adrenergic agonists |
JP2005520805A (en) | 2002-01-11 | 2005-07-14 | イーライ・リリー・アンド・カンパニー | 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists |
US20040127733A1 (en) | 2002-10-31 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
JPWO2004106290A1 (en) * | 2003-05-14 | 2006-07-20 | キッセイ薬品工業株式会社 | Aminoalcohol derivatives, pharmaceutical compositions containing them, and uses thereof |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
DE102004021779A1 (en) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, process for their preparation and their use as medicines |
JP4879988B2 (en) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
DE102005052127A1 (en) | 2005-10-28 | 2007-05-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel indole beta-agonists, process for their preparation and their use as pharmaceuticals |
JP2007145819A (en) * | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | Pharmaceutical composition |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
CA2740772A1 (en) | 2008-10-09 | 2010-04-15 | Asahi Kasei Pharma Corporation | Indazole compounds |
JPWO2010041568A1 (en) | 2008-10-09 | 2012-03-08 | 旭化成ファーマ株式会社 | Indazole derivatives |
EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2362731B1 (en) | 2008-10-31 | 2016-04-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
KR101668514B1 (en) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
EP2687507B1 (en) | 2011-03-14 | 2016-03-09 | Taisho Pharmaceutical Co., Ltd. | Nitrogen-containing condensed heterocyclic compound |
KR20150036245A (en) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | Antidiabetic tricyclic compounds |
ES2394349B1 (en) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Use of selective beta-3 adrenergic receptor agonists for the treatment of pulmonary hypertension |
CN104994848A (en) | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0091749A3 (en) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
-
1995
- 1995-04-18 IL IL11341095A patent/IL113410A/en not_active IP Right Cessation
- 1995-04-21 JP JP52779795A patent/JP3149186B2/en not_active Expired - Fee Related
- 1995-04-21 CA CA002187932A patent/CA2187932A1/en not_active Abandoned
- 1995-04-21 CZ CZ963151A patent/CZ315196A3/en unknown
- 1995-04-21 HU HU9602951A patent/HUT76442A/en unknown
- 1995-04-21 NZ NZ284718A patent/NZ284718A/en unknown
- 1995-04-21 WO PCT/US1995/004956 patent/WO1995029159A1/en not_active Application Discontinuation
- 1995-04-21 EP EP95917116A patent/EP0757674A1/en not_active Ceased
- 1995-04-21 CN CN95192821A patent/CN1149869A/en active Pending
- 1995-04-21 AU AU23937/95A patent/AU687558B2/en not_active Ceased
- 1995-04-21 SK SK1361-96A patent/SK136196A3/en unknown
- 1995-04-21 PL PL95316969A patent/PL316969A1/en unknown
-
1996
- 1996-10-25 FI FI964314A patent/FI964314A/en unknown
- 1996-10-25 NO NO964548A patent/NO964548L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU687558B2 (en) | 1998-02-26 |
MX9605192A (en) | 1997-09-30 |
PL316969A1 (en) | 1997-03-03 |
FI964314A0 (en) | 1996-10-25 |
JPH09512275A (en) | 1997-12-09 |
WO1995029159A1 (en) | 1995-11-02 |
EP0757674A1 (en) | 1997-02-12 |
IL113410A (en) | 1999-11-30 |
SK136196A3 (en) | 1997-05-07 |
CZ315196A3 (en) | 1997-08-13 |
FI964314A (en) | 1996-10-25 |
AU2393795A (en) | 1995-11-16 |
HU9602951D0 (en) | 1996-12-30 |
HUT76442A (en) | 1997-09-29 |
JP3149186B2 (en) | 2001-03-26 |
NZ284718A (en) | 1998-02-26 |
NO964548L (en) | 1996-12-23 |
IL113410A0 (en) | 1995-07-31 |
CN1149869A (en) | 1997-05-14 |
CA2187932A1 (en) | 1995-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO964548D0 (en) | Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesity | |
NO993646D0 (en) | Thiazole benzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity | |
ZA953336B (en) | Substituted sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | |
EP0915847A4 (en) | Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
NO20063000L (en) | Combination and pharmaceutical composition for the treatment of diabetes and its use. | |
GB9619331D0 (en) | Selective ›3 agonists for the treatment of diabetes and obesity | |
NO976063D0 (en) | Procedure for the treatment of diabetes | |
ID23600A (en) | TIAZOLIDIN AND OKSAZOLIDIN DERIVATES, THE PRODUCTION AND USE OF TREATMENT (TREATMENT OF P-950453) | |
NL300066I1 (en) | Treatment of obesity. | |
NO161366C (en) | NEW 1,3-CYCL HEXANDON DERIVATIVES AND USE THEREOF AS HERBICID AGENT. | |
DE59509714D1 (en) | Osteosynthetic fixator | |
NO972451D0 (en) | 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and preparations and process for use thereof | |
NO307254B1 (en) | 1,2,4-oxadiazole derivatives and parasite pesticides containing the same | |
IS1966B (en) | Peptide p277 analogues and pharmaceutical compositions containing them, for the treatment or diagnosis of diabetes | |
NO20012727L (en) | 3,4,5-trisubstituted arylnitron compounds and pharmaceutical compositions containing the same | |
NO179852C (en) | Mixture comprising 1,2-benzisothiazolin-3-one and use thereof | |
DK0643922T3 (en) | Flavoring agent | |
DK432289A (en) | WATER-EXPLOSIBLE, AIR-WAVING COATING AGENT AND ITS APPLICATION | |
FI941776A0 (en) | Process for the preparation of 1,2,4-thiadiazoles | |
NO860733L (en) | N- (2-CHLORO-4-TRIFLUORMETHYLPHENYL) -3-TRIFLUORMETHYL-BENZENESULPHONAMIDE DERIVATIVE, PROCEDURE FOR THE PREPARATION OF THIS, AND FUNGICID AGENTS CONTAINING THIS. | |
NO900643L (en) | PROCEDURE FOR THE PREPARATION AND USE OF 2,3,23-TRIHYDROXY-URS-12 UNITS AND THEIR DERIVATIVES. | |
NO893892D0 (en) | ANTIMICROBIOLOGICAL COMPOSITION AND PROCEDURE FOR USE. | |
DK631989D0 (en) | ANTI-PLASTER AND / OR AGENT FOR THE TREATMENT OF DISORDERS | |
DE69516111D1 (en) | LIQUID CRYSTAL COMPOUNDS, MIXTURES AND DEVICES | |
NO905543L (en) | PROCEDURE FOR THE PREPARATION AND USE OF AMINOPYRIDINYLMETHANOLS AND AMINOMETHYLPYRIDINAMINES. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |